Relyvrio

Active Ingredient(s): Sodium Phenylbutyrate + Taurursodiol
FDA Approved: * September 29, 2022
Pharm Company: * AMYLYX
Category: Genetic Disorders
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Relyvrio Oral Powder, for Suspension
NDC: 73063-035
Labeler:
Amylyx Pharmaceuticals Inc

Related Brands

Drugs with the same active ingredients